AB Science will host a live webcast on Tuesday May 25, 2021 on masitinib results in Prostate Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
PRESS RELEASE
AB SCIENCE WILL HOST A LIVE WEBCAST ON TUESDAY MAY 25, 2021 ON MASITINIB’S RESULTS IN PROSTATE CANCER
Paris, May 21, 2021, 6pm CET
AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on May 25, 2021 with key opinion leaders to discuss recently reported results from the Phase 2B/3 masitinib trial in prostate cancer.
The webcast call will be held on Tuesday May 25, 2021 from 6.30pm to 7.30pm CET (12.30pm to 1.30pm ET).
The webcast will feature presentations by three Key Opinion Leaders:
Stéphane Oudard, MD, PhD, Chief of the Oncology Clinical and Translational Research Unit at the Georges Pompidou Hospital in Paris, France
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
AB Science announces the signing of an exclusive licensing agreement with the University of .
AB ScienceApril 6, 2021 GMT
PRESS RELEASE
AB SCIENCE ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF CHICAGO TO CONDUCT RESEARCH FOR THE PREVENTION AND TREATMENT OF COVID-19 WITH MASITINIB AND OTHER AB SCIENCE PROPRIETARY DRUGS
Paris, April 6 2021, 8am CET
AB Science SA (Euronext - FR0010557264 - AB), together with the University of Chicago, to
AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Innate Pharma to Host Key Opinion Leader Discussion on the Potential Role of Lacutamab Across .
INNATE PHARMAFebruary 3, 2021 GMT
MARSEILLE, France, Feb. 03, 2021 (GLOBE NEWSWIRE) Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual key opinion leader (KOL) discussion focused on the potential role of its lead investigational drug candidate, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas. The event will be held virtually on Tuesday, February 9, 2021 at 2:00 p.m. CET / 8:00 a.m. ET.